Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Forecast for the Uveitis Treatment Market Growth in 2025?
In recent years, there has been significant growth in the market size for uveitis treatment. The market which is expected to increase from $1.43 billion in 2024 to $1.54 billion in 2025 with a compound annual growth rate (CAGR) of 8.1%. This expansion in the past era has been driven by higher incidence of autoimmune diseases, increasing elderly population, a growing number of uveitis cases, burgeoning awareness among medical experts about the significance of prompt diagnosis and treatment, and an increasing occurrence of infectious diseases.
What Is the Forecast for the Uveitis Treatment Market Size Through 2029?
It is anticipated that the market size for uveitis treatment will experience robust growth in the coming years, escalating to 2.08 billion by 2029 with a compound annual growth rate (CAGR) of 7.8%. The growth projected within this timeframe can be ascribed to factors such as enhanced accessibility of healthcare services, a surge in age-associated eye diseases, an increase in the elderly demographic, the rise in research endeavors, and heightened consciousness of eye health in people. Key trends projected within this forecast period encompass the proliferation of targeted therapies, progress in laser surgery, the emergence of innovative drug delivery systems, headways in ophthalmology diagnostic equipment, and the rising adoption of sustained-release drug delivery systems.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21313&type=smp
What are the Key Market Players in Uveitis Treatment Market and How They’re Evolving?
Major companies operating in the uveitis treatment market are Merck & Co. Inc., AbbVie Inc., Novartis AG, Regeneron Pharmaceuticals Inc., Kubota Vision Inc., UCB S.A., Sun Pharmaceutical Industries Ltd., Bausch & Lomb Incorporated, Horizon Therapeutics plc, Cipla Ltd., Santen Pharmaceutical Co. Ltd., Galapagos NV, ANI Pharmaceuticals Inc., EyePoint Pharmaceuticals Inc., Entod Pharmaceuticals Ltd., Sirion Therapeutics Inc., Kiora Pharmaceuticals Inc., Lux Biosciences Inc., Inflammasome Therapeutics Inc., Clearside Biomedical Inc.
What Are the Primary Growth Drivers in the Uveitis Treatment Market?
The escalating prevalence of autoimmune disorders is anticipated to fuel the expansion of the uveitis treatment market. Autoimmune disorders encompass a variety of illnesses where the body’s immune system mistakenly assaults and destroys its healthy cells, tissues, or organs. The upsurge in these conditions is propelled by elements such as genetic vulnerability, environmental catalysts, and modifications in lifestyle and immune system actions. Uveitis treatment aids in the management of autoimmune disorders by diminishing inflammation, repressing the overactivity of the immune system, and averting vision loss linked to inflammatory eye conditions related to autoimmunity. For example, Versorgungsatlas, a healthcare data analytics firm based in Germany, reported in November 2024 that in 2022, out of 73,241,305 insured persons, 6,304,340 were identified with at least one autoimmune disorder, leading to a crude prevalence rate of 8.61%. Thus, the escalating prevalence of autoimmune disorders is stimulating the expansion of the uveitis treatment market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=21313&type=smp
What Are the Leading Segments in the Global Uveitis Treatment Industry?
The uveitis treatment market covered in this report is segmented –
1) By Indication: Anterior Uveitis, Intermediate Uveitis, Posterior Uveitis, Panuveitis
2) By Route Of Administration: Topical, Systemic, Injectable
3) By Cause: Infectious, Non-infectious
4) By Treatment: Corticosteroids, Immunosuppressant, Monoclonal Antibodies, Cycloplegic Agents, Antibiotics, Antivirals, Antifungal, Analgesics
5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels
Subsegments:
1) By Anterior Uveitis: Infectious Anterior Uveitis, Non-Infectious Anterior Uveitis
2) By Intermediate Uveitis: Infectious Intermediate Uveitis, Non-Infectious Intermediate Uveitis
3) By Posterior Uveitis: Infectious Posterior Uveitis, Non-Infectious Posterior Uveitis
4) By Panuveitis: Infectious Panuveitis, Non-Infectious Panuveitis
What Are the Key Market Trends in the Uveitis Treatment Industry?
Leading firms in the uveitis treatment market are prioritizing the creation of cutting-edge devices like sustained-release intravitreal implants to enhance patient adherence. These implants are long-lasting drug delivery systems inserted in the eye for controlled and extended drug release. For example, in February 2022, the US biopharmaceutical company, Alimera Sciences, introduced ILUVIEN in Spain. ILUVIEN is a sustained-release intravitreal implant engineered to manage non-infectious posterior uveitis (NIPU). The implant provides direct delivery of the drug fluocinolone acetonide into the eye, which is gradually released over a period of up to 36 months, offering prolonged therapeutic intervention to lessen inflammation and prevent recurrent NIPU flare-ups. It is the only one of its kind for this specific application, aiming to reduce injection frequency and improve patient prognosis with a more persistent, long-term effect.
Access The Full Report Here:
https://www.thebusinessresearchcompany.com/report/uveitis-treatment-global-market-report
What Is the Regional Outlook for the Uveitis Treatment Market?
North America was the largest region in the uveitis treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the uveitis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21313
This Report Delivers Insight On:
1. How big is the uveitis treatment market, and how is it changing globally?
2. Who are the major companies in the uveitis treatment market, and how are they performing?
3. What are the key opportunities and risks in the uveitis treatment market right now?
4. Which products or customer segments are growing the most in the uveitis treatment market?
5. What factors are helping or slowing down the growth of the uveitis treatment market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model